Gemcitabine and Radiotherapy in the Treatment of Uterine Cervical Cancer Patients at Phramongkutklao Hospital
Phanida Jarruwale MD*, Yawana Tanapat MD*, Pote Aimpun MD, MSc, DrPH**
Affiliation : * Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Phramongkutklao Hospital, Bangkok, Thailand ** Department of Military and Community Medicine, Phramongkutklao College of Medicine, Bangkok 10400 Thailand
Objectives : To determine response, complication and survival of uterine cervical cancer patients treated with
concurrent gemcitabine radiotherapy.
Materials and Methods : A retrospective review of medical records of 41 patients with uterine cervical cancer
patients, stage IIB and above treated with concurrent gemcitabine radiotherapy from August 2000 to August
2003.
Results : At 6 and 12 months of follow up, the complete response rate was 75.6% and 65.9%. The cumulative
probability of survival at 6 and 12 months after treatment was 0.93 and 0.85. The main complications were
mild hematologic and nonhematologic toxicities.
Conclusion : Concurrent gemcitabine radiotherapy provided a satisfactory response in patients with uterine
cervical cancer with mild toxicity. Long term follow up data is necessary to determine the recurrent rate
of this regimen.
Keywords : Cervical cancer, Gemcitabine, Radiotherapy
